| Expression pattern: |
DN |
| Associated gene: |
AGO2, TXNIP |
| Associated microRNA: |
miR-27a-3p |
| Biological function: |
Suppresses RCC proliferation, migration, invasion, tumor growth and metastasis; decreased cRAPGEF5 is associated with RCC progression and poor prognosis. |
| Molecular mechanism: |
cRAPGEF5 acts as a miR-27a-3p sponge to prevent TXNIP downregulation, thereby suppressing RCC progression via the miR-27a-3p/TXNIP pathway. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); circRIP; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Transwell Assay; In Vivo Animal Model; H&E Staining; Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
cRAPGEF5 downregulation correlated positively with aggressive clinical characteristics and independently predicted poor overall survival and recurrence-free survival; cRAPGEF5 may serve as a promising prognostic biomarker and novel therapeutic target for RCC patients. |
| Description: |
cRAPGEF5 is a human RAPGEF5-derived circRNA that is significantly downregulated in RCC tissues. It acts as a tumor suppressor by sponging miR-27a-3p and preventing TXNIP downregulation, thereby inhibiting RCC cell proliferation, migration, invasion, tumor growth and metastasis. Clinically, reduced cRAPGEF5 expression is associated with aggressive features and poor OS/RFS, suggesting prognostic and therapeutic potential. |
| Confidence score: |
0.8912 |